{
  "source": "PA-Notification-Samsca.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1282-7\nProgram Prior Authorization/Notification\nMedication Samsca® (tolvaptan)\nP&T Approval Date 6/2019, 6/2020, 6/2021, 6/2022, 6/2023, 6/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nSamsca is a selective vasopressin V -receptor antagonist indicated for the treatment of\n2\nclinically significant hypervolemic and euvolemic hyponatremia (serum sodium < 125\nmEq/L or less marked hyponatremia that is symptomatic and has resisted correction with\nfluid restriction), including patients with heart failure and Syndrome of Inappropriate\nAntidiuretic Hormone (SIADH).1\nLimitations of Use:\n• Patients requiring intervention to raise serum sodium urgently to prevent or to treat\nserious neurological symptoms should not be treated with Samsca.\n• It has not been established that Samsca provides a symptomatic benefit to patients.\n2. Coverage Criteriaa:\nA. Hypervolemic or Euvolemic Hyponatremia\n1. Samsca will be approved based on all of the following:\na. One of the following:\n(1) Diagnosis of clinically significant euvolemic hyponatremia\n-OR-\n(2) Diagnosis of clinically significant hypervolemic hyponatremia\n-AND-\nb. Patient has not responded to fluid restriction\n-AND-\nc. Treatment has been initiated or re-initiated in a hospital setting prior to discharge\nAuthorization will be issued for 30 days.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2025 UnitedHealthcare Services Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Sams",
    "y, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Samsca [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc.; April\n2021.\nProgram Prior Authorization/Notification – Samsca (tolvaptan)\nChange Control\n6/2019 New program.\n6/2020 Annual review. No changes to criteria.\n6/2021 Annual review. No changes to criteria. Updated background and\nreferences.\n6/2022 Annual review. No changes to criteria. Updated background and\nreferences.\n6/2023 Annual review with no changes to criteria. Added state mandate\nfootnote.\n6/2024 Annual review with no changes to criteria. Updated formatting of\nbackground.\n6/2025 Annual review with no changes to criteria.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}